Pfizer anti covid pill, Ema starts drug review

The European drug agency Ema announces the launch of a review on Pfizer’s anti-covid pill. “Ema – explains the EU regulatory body – is examining the data currently available” on the pill which should represent a step forward on the home care front, “and launches this review to support national authorities who could decide on its early use. , for example in emergency contexts, before marketing authorization “. The CHMP Committee for Medicinal Products for Human Use – reports the EMA – will examine the data of a study comparing the effect of Paxlovid compared to placebo in patients with mild to moderate Covid, not hospitalized, but at risk of progression to the disease serious. Preliminary results indicate that the treatment reduced the risk of hospitalization or death compared to placebo when administered within 3 to 5 days of onset of symptoms. The CHMP will also examine the data on the quality and safety of the drug. “Although a more complete rolling review is expected to begin before a possible application for marketing authorization – the agency specifies – this review will provide recommendations to EU level as soon as possible, so that they can be used by national authorities wishing to make evidence-based decisions on early use of the medicine “.